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Letters to the EditorIL28B rs12979860 is not associated with histologic features
of NAFLD in a cohort of Caucasian North American patientsTo the Editor:
We read with interest the paper by Petta et al. evaluating IL28B in
160 patients with non-alcoholic fatty liver disease (NAFLD). The
authors described the association of IL28B with both inﬂamma-
tion and ﬁbrosis, though the association with ﬁbrosis was not sig-
niﬁcant after adjusting for inﬂammation [1]. Interestingly,
steatosis, the hallmark of fatty liver disease, was not associated
with IL28B in the study by Petta et al.
We had previously described an association of IL28B
rs12979860 with serum lipids and steatosis [2,3], both of which
was conﬁrmed in subsequent studies [4–6]. While steatosis was
concordantly found to be associated with the less favorable
IL28B genotypes (CT and TT) in patients with hepatitis C, a rela-
tion to inﬂammation was not reported.
Thoughwebelieved the effect of IL28B to be relatively limited to
HCV, in light of the ﬁndings reported by Petta et al., we evaluated
the role of IL28B in our cohort of NAFLD patients. Patients were
recruited at two different sites, the ‘‘Duke University Outpatient
Fatty LiverClinic’’ and ‘‘DurhamRegionalHospital’’,wherepatients
are evaluated for bariatric surgery.
195 Caucasian patients with biopsy-proven NAFLD and DNA
available for genetic testing were evaluated for IL28B rs12979860.
Histologic features as deﬁned by the Non-alcoholic Steatohep-
atitis Clinical ResearchNetwork [7] include steatosis grade (0–1 vs.
2–3), ﬁbrosis stage (0–2 vs. 3–4), lobular inﬂammation grade (0–1
vs.2–3), hepatocyte ballooning (0–1 vs.2) andNAFLDactivity score
(NAS, <5 vs.P5). Frequencies andmeanswere generated using SAS
version9.2usingprocedures PROCFREQandPROCMEANS, respec-
tively (SAS Systems, Cary, NC). Logistic regression (PROC LOGISTIC)
was utilized to determine the relationship of IL28B and histological
outcomes. Based on the Petta et al. approach, a dominant genetic
model was employed such that the CC genotype was compared
to CT/TTgenotypes. Bivariatemodelswere tested aswell asmodels
adjusting for age, gender, diagnosis of diabetes mellitus (DMdx),
body mass index (BMI) and site of recruitment (Bariatric Surgery
Program or Liver Clinic).A) IL28B rs12979860 genotype in relation to histological features of NAFLD. (B) Odds ratios (and corresponding p values in brackets) for rs12979860 (CC vs.
d covariates: age, sex (male vs. female), diabetes mellitus diagnosis (DMdx) (yes vs. no), BMI, and site of recruitment.
CC (%) CT (%) TT (%) p value
sis 0-1 (n = 94) 51 (54.26) 34 (36.17) 9 (9.57) 0.1955
2-3 (n = 98) 44 (44.9) 45 (45.92) 9 (9.18)
ation 0-1 (n = 148) 75 (50.68) 60 (40.54) 13 (8.78) 0.1933
2-3 (n = 34) 13 (38.24) 16 (47.06) 5 (14.71)
ning 0-1 (n = 159) 81 (50.94) 63 (39.62) 15 (9.43) 0.3604
2 (n = 31) 13 (41.94) 15 (48.39) 3 (9.68)
is 0-2 (n = 168) 81 (48.21) 70 (41.67) 17 (10.12) 0.7257
3-4 (n = 27) 14 (51.85) 11 (40.74) 2 (7.41)
0-4 (n = 143) 76 (53.15) 53 (37.06) 14 (9.79) 0.0845
≥5 (n = 49) 19 (38.78) 26 (53.06) 4 (8.16)
rs12979860 Site Age Sex DMdx BMI
sis grade (2-3 vs. 0-1) 0.659 (0.192) 0.251 (0.0029) 0.992 (0.63) 0.969 (0.92) 1.233 (0.56) 1.012 (0.63)
r inflammation (2-3 vs. 0-1) 0.522 (0.132) 0.219 (0.0148) 0.994 (0.79) 0.634 (0.31) 1.991 (0.13) 0.979 (0.5)
cellular ballooning (2 vs. 0-1) 0.795 (0.636) 0.013 (<0.0001) 1.033 (0.19) 0.318 (0.024) 1.883 (0.20) 1.099 (0.019)
is stage 
. 0-2 as in Petta et al., [1]) 1.260 (0.622) 0.073 (0.0005) 1.038 (0.12) 1.1577 (0.76) 3.062 (0.022) 1.095 (0.013)
+ vs. 0-4) 0.524 (0.094) 0.102 (<0.0001) 0.985 (0.41) 0.399 (0.024) 1.643 (0.24) 1.009 (0.75)
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The distribution of rs12979860 genotypes in our dataset was
similar to the population described by Petta et al., and typical for
a Caucasian population with 48.72% of the subjects homozygous
for the C allele, 41.54% heterozygous, and 9.74% homozygous for
the T allele.
However, in contrast to Petta et al., we did not ﬁnd a signiﬁ-
cant role of IL28B in relation to histological characteristics of
NAFLD (Table 1A). Results did not change substantially when
the analysis was adjusted for age, gender, DMdx, BMI and recruit-
ment site. The adjusted model, however, conﬁrmed the expected
role for BMI and diabetes mellitus in regard to histological
features of NAFLD (Table 1B).
Importantly, the trend for inﬂammation was reversed. While
64% of patients with increased inﬂammation in the study by
Petta et al. had the CC genotype, less than 40% of patients with
severe inﬂammation in our study had the CC genotype.
Furthermore, the NAFLD Activity Score, which showed borderline
signiﬁcance in the adjusted model (p = 0.0937), became less
signiﬁcant when an additive model (CC>CT>TT) was used
(p = 0.2243). Similar to the trend observed with inﬂammation,
the NAS tended to be lower in patients with rs12979860 CC geno-
type, and therefore in the opposite direction to the observation
by Petta et al.
Thus, in summary, our data do not show a signiﬁcant associ-
ation of IL28B and histological features in North American Cauca-
sian patients with NAFLD.
However, almost all of our patients were obese, while only
40% of the patients in Petta et al.’s study were obese (BMI >30).
It would, therefore, be interesting to know if the association
reported by Petta et al. change when stratifying their cohort
according to BMI group, <25, 25–30, and >30 BMI.Financial support
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To the Editor:
We recently reported a link between interleukin 28B (IL28B)
rs12979860 genotype and severity of liver disease, in a cohort
of 160 biopsy-proven non-alcoholic fatty liver disease (NAFLD)
patients, forty percent of them with obesity, and with a mean
age of 45.6 years [1]. In particular, we observed that the IL28B
CC genotype, associated in chronic hepatitis C (CHC) with a
higher rate of sustained virological response after antiviral ther-
apy [2], in NAFLD patients was independently associated with a
higher prevalence of moderate-severe liver lobular inﬂammation
and ﬁbrosis [1]. Our results were in line with other data on CHC
patients suggesting a link, even if not conﬁrmed in other studies,
between IL28B CC genotype and severity of liver disease [3,4].
In this complex picture, we read with great interest data
reported by Garrett and colleagues [5] on the association between
IL28B genotype and severity of histological features in NAFLD
patients. Speciﬁcally, the authors did not identify any association
among IL28B status and steatosis, inﬂammation, ballooning and
ﬁbrosis in their cohort of NAFLDpatients [5]. However, as correctly
highlighted by the same authors, they enrolled a cohort of severe
obese NAFLD patients evaluated for bariatric surgery [5], and
therefore very different from our enrolled cohort [1]. In particular,
it should be possible to assume that the genetic backgroundJournal of Hepatology 2013 vol. 58 j 402–404 403
